A vaccine administered during pregnancy is significantly cutting hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a decrease of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and transferring immunity through the placenta. A major new study analysing nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the timeframe when infants are particularly susceptible to the virus. RSV affects roughly half of all newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the vaccine safeguards at-risk babies
RSV, or respiratory syncytial virus, is a common respiratory infection that affects roughly half of all newborns in their first few months of life. The virus can vary from causing mild, cold-like symptoms to causing severe chest infections that leave babies struggling to breathe and feed. In the most severe cases, the inflammation in the lungs becomes life-threatening, with small numbers of infants dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of serious RSV infections: “In babies with bad infections you can see their chest and lungs working hard, as they try to pull enough oxygen in. This is extremely frightening as a parent, frightening with good reason.”
The pregnancy vaccine works by stimulating the mother’s body’s defences to produce defence proteins, which are then transferred to the developing baby through the placenta. This maternal immunity offers newborns with immediate protection from the point of delivery, exactly when they are highly susceptible to RSV. The new study shows that protection reaches nearly 85 per cent when the vaccine is given four weeks or more before delivery. Even shorter intervals between vaccination and birth can still deliver substantial defence, with evidence indicating that a two-week gap is sufficient to shield babies delivered prematurely. Dr Watson advises pregnant women to receive the vaccine on schedule, whilst observing that protection remains possible even if given later in the third trimester.
- Nearly 85 per cent coverage when vaccinated four weeks before birth
- Maternal antibodies passed through placenta protect newborns from day one
- Protection achievable with 2-week gap before premature birth
- Vaccination during the third trimester still provides meaningful infant protection
Strong evidence from recent research
The effectiveness of the RSV vaccine administered during pregnancy has been established through a extensive research programme undertaken in England, analysing data from approximately 300,000 babies born between September 2024 and March 2025. This constitutes approximately 90% of all births during that six-month timeframe, providing comprehensive and reliable information of the vaccine’s real-world impact. The study’s conclusions have been supported by the UK Health Security Agency as showing “excellent protection” for newborns during their earliest and most vulnerable period. The breadth of this investigation gives healthcare professionals and parents-to-be with trust in the vaccine’s established performance across different groups and contexts.
The results paint a compelling picture of the vaccine’s ability to protect. More than 4,500 babies were hospitalised with RSV throughout the study period, with the vast majority being infants whose mothers had not received the vaccination. This clear distinction underscores the vaccine’s vital importance in protecting against serious illness in newborns. The drop in hospital admissions surpassing 80 per cent represents a substantial public health milestone, helping to prevent thousands of infants from experiencing the distressing and potentially serious symptoms associated with severe RSV infection. These findings strengthen the importance of the vaccination programme established in the UK in 2024.
Research approach and coverage
The research reviewed birth and hospitalisation records from England over a six-month timeframe, capturing data on approximately 90 per cent of all births during this timeframe. By examining nearly 300,000 babies born to vaccinated and unvaccinated mothers, researchers were able to identify direct comparisons of RSV infection levels and hospitalisations. The large sample size and thorough nature of the data collection ensured that findings were statistically significant and indicative of the general population, rather than individual cases or limited subgroups.
The study specifically monitored hospital admissions for RSV among infants born to mothers who had received the vaccine at varying intervals before delivery. This allowed researchers to identify the least amount of time between vaccination and birth for best possible protection, as well as to determine whether protection stayed significant with shorter intervals. The methodology assessed real-world outcomes rather than laboratory-based settings, providing practical evidence of how the vaccine functions when given across different clinical contexts and patient circumstances throughout the third trimester of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Comprehending RSV and the risks
Respiratory syncytial virus, typically known as RSV, is one of the leading causes of hospitalisation in infants under one year of age across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their early months of life, with severity changing substantially from minor cold-type symptoms to serious, potentially fatal chest infections. Over 20,000 infants require serious hospital treatment for RSV annually in the UK alone, placing enormous strain on paediatric wards and neonatal units during busier periods.
The infection causes deep inflammation in the lungs and airways, making it perilously hard for vulnerable newborns to breathe and feed effectively. Parents often witness their babies visibly struggling, their chests rising whilst they try to pull sufficient oxygen into their damaged lungs. Whilst the majority of babies get better with clinical support, a limited though important number die from respiratory syncytial virus complications yearly, making immunisation programmes a essential public health objective for safeguarding the youngest and most vulnerable members of society.
- RSV causes inflammation in lungs, leading to serious respiratory problems in babies
- Nearly 50% of newborns acquire the virus in their first few months of life
- Symptoms span from mild colds to life-threatening chest infections requiring hospitalisation
- More than 20,000 UK infants need serious hospital treatment for RSV annually
- A small number of infants die from RSV complications annually in the UK
Uptake rates and professional guidance
Since the RSV vaccine programme launched in 2024, health officials have stressed the significance of pregnant women receiving their jab at the optimal time for greatest protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has underscored that timing is crucial for ensuring newborns receive the most robust immunity from birth. Whilst the research shows that vaccination at least four weeks before delivery offers nearly 85% protection, experts recommend women to receive their vaccine as early as possible from 28 weeks of pregnancy forward to maximise the antibodies passed to their babies through the placenta.
The communication from health authorities remains clear: pregnant women ought to prioritise vaccination during their final three months, even if circumstances mean they cannot get vaccinated at the best timing. Dr Watson has reassured pregnant women that protection remains still achievable with shorter intervals between immunisation and delivery, including even a fourteen-day window for those delivering slightly early. This flexible approach recognises the realities of pregnancy and childbirth whilst ensuring strong safeguarding for at-risk infants during their earliest and most vulnerable period when RSV represents the highest danger of serious illness.
Regional variations in immunisation
Whilst the RSV vaccine programme has been rolled out across England, uptake rates and implementation timelines have varied across various areas and NHS trusts. Certain regions have attained higher vaccination coverage among eligible pregnant women, whilst others continue working to boost understanding and availability of the jab. These regional differences demonstrate variations in medical facilities, engagement approaches, and community involvement initiatives, though the national data shows robust and reliable protection regardless of geographical location.
- NHS trusts rolling out multiple messaging strategies to engage with pregnant women
- Geographic variations in vaccine uptake rates in different parts of England necessitate strategic intervention
- Community health services modifying schemes to meet community needs and circumstances
Real-world impact and parent viewpoints
The vaccine’s outstanding effectiveness provides real advantages for families across the United Kingdom. With more than 20,000 babies admitted to hospital annually due to RSV prior to the launch of this safeguarding intervention, the 80% drop in admissions represents thousands of infants protected against severe infection. Parents no longer face the distressing scenario of watching their newborns gasping for air or labour to feed, symptoms that define severe RSV infections. The vaccine has substantially transformed the landscape of neonatal respiratory health, offering expectant mothers a proactive tool to safeguard their youngest infants during those crucial first weeks.
For families like that of Malachi, whose acute RSV infection led to devastating brain damage, the vaccine’s introduction carries deep personal significance. His mother’s promotion of the jab underscores the profound consequences that vaccine-preventable disease can inflict on young children and their families. Whilst Malachi’s experience comes before the vaccine programme, his story strikes a chord with parents now provided with protection. The knowledge that such grave complications—hospital stay, oxygen dependency, neurological damage—are now largely avoidable has offered substantial reassurance to pregnant women in their third trimester, converting what was once an inevitable seasonal threat into a manageable risk.